Publicacions - Fundació Institut d'Investigació en Ciències de la
Publicacions - Fundació Institut d'Investigació en Ciències de la
Publicacions - Fundació Institut d'Investigació en Ciències de la
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Ribera JM, Oriol A, González M, Vidriales B, Brunet S, Esteve J, Del Potro E, Rivas C, Mor<strong>en</strong>o MJ, Tormo<br />
M, Martín-Reina V, Sarrá J, Parody R, <strong>de</strong> Oteyza JP, Bureo E, Bernal MT; Programa Español <strong>de</strong><br />
Tratami<strong>en</strong>to <strong>en</strong> Hematología; Grupo Español <strong>de</strong> Trasp<strong>la</strong>nte Hemopoyético Groups.<br />
Concurr<strong>en</strong>t int<strong>en</strong>sive chemotherapy and imatinib before and after stem cell transp<strong>la</strong>ntation in newly<br />
diagnosed Phi<strong>la</strong><strong>de</strong>lphia chromosome-positive acute lymphob<strong>la</strong>stic leukemia.<br />
HAEMATOL-HEMATOL J 2010 Jan;95(1):87-95. Epub 2009 Oct 1.<br />
IF: 6,532<br />
Salido, M; Baro, C; Oscier, D; Stamatopoulos, K; Dier<strong>la</strong>mm, J; Matutes, E; Traverse-Gleh<strong>en</strong>, A; Berger, F;<br />
Felman, P; Thieblemont, C; Gesk, S; Athanasiadou, A; Davis, Z; Gardiner, A; Mil<strong>la</strong>, F; Ferrer, A; Mollejo,<br />
M; Ca<strong>la</strong>sanz, MJ; Flor<strong>en</strong>sa, L; Espinet, B; Luno, E; Wlodarska, I; Verhoef, G; Garcia-Granero, M; Sa<strong>la</strong>r, A;<br />
Papadaki, T; Serrano, S; Piris, MA; Sole, F<br />
Cytog<strong>en</strong>etic aberrations and their prognostic value in a series of 330 spl<strong>en</strong>ic marginal zone B-cell<br />
lymphomas: a multic<strong>en</strong>ter study of the Spl<strong>en</strong>ic B-Cell Lymphoma Group<br />
BLOOD 2010 Sep 2;116(9):1479-88. Epub 2010 May 17.<br />
IF: 10,558<br />
Sancho, JM; Orfao, A; Quijano, S; Garcia, O; Panizo, C; Perez-Ceballos, E; Deb<strong>en</strong>, G; Sa<strong>la</strong>r, A; Gonzalez-<br />
Barca, E; Alonso, N; Garcia-Ve<strong>la</strong>, JA; Capote, J; P<strong>en</strong>alver, FJ; Prov<strong>en</strong>cio, M; Arias, J; P<strong>la</strong>za, J; Caballero, D;<br />
Morado, M; Feliu, E; Ribera, JM<br />
Clinical significance of occult cerebrospinal fluid involvem<strong>en</strong>t assessed by flow cytometry in non-<br />
Hodgkin's lymphoma pati<strong>en</strong>ts at high risk of c<strong>en</strong>tral nervous system disease in the rituximab era<br />
EUR J HAEMATOL 2010 Oct;85(4):321-8. doi: 10.1111/j.1600-0609.2010.01478.x. Epub 2010 Jul 28.<br />
IF: 2,785<br />
Xicoy, B; Ribera, JM; Mate, JL; Tapia, G; Morga<strong>de</strong>s, M; Navarro, JT; Sanz, C; Ariza, A; Feliu, E<br />
Immunohistochemical expression profile and prognosis in pati<strong>en</strong>ts with diffuse <strong>la</strong>rge B-cell lymphoma<br />
with or without human immuno<strong>de</strong>fici<strong>en</strong>cy virus infection<br />
LEUKEMIA LYMPHOMA 2010; NOV, 51 (11) 2063-2069<br />
IF: 2,492<br />
Projectes<br />
FERRA COLL, CHRISTELLA MARIE<br />
FIS - Núm. Exp.: PI070444<br />
Re<strong>la</strong>ción <strong>de</strong> los valores séricos <strong>de</strong> <strong>la</strong> procalcitonina (PCT) y otros reactantes <strong>de</strong> fase aguda con <strong>la</strong>s<br />
complicaciones y superviv<strong>en</strong>cia <strong>de</strong> paci<strong>en</strong>tes con hemopatías malignas que requier<strong>en</strong> ingreso <strong>en</strong> Unidad<br />
<strong>de</strong> Cuidados Int<strong>en</strong>sivos.<br />
Durada: 3 anys - (2007-2010)<br />
Import Concedit: 28.850 €<br />
RIBERA SANTASUSANA, JOSEP MARIA<br />
<strong>Institut</strong>o <strong>de</strong> Salud Carlos III - Núm. Exp.: PI10/01417<br />
Estudio <strong>de</strong> <strong>la</strong> frecu<strong>en</strong>cia y significado pronóstico <strong>de</strong> <strong>la</strong>s <strong>de</strong>leciones/mutaciones <strong>de</strong>l g<strong>en</strong> IKZF1 y <strong>de</strong>l estado<br />
<strong>de</strong> hipermeti<strong>la</strong>ción <strong>de</strong> los g<strong>en</strong>es hsa-miR-375, HDPR1 (DACT1), SHP1 (PTPN6), P16 (CDKN2A), hsa-miR-9-3<br />
y DBC1 <strong>en</strong> paci<strong>en</strong>tes adultos con leucemia aguda linfoblástica sin reord<strong>en</strong>ami<strong>en</strong>to BCR-ABL1 incluidos <strong>en</strong><br />
protocolos <strong>de</strong> tratami<strong>en</strong>to adaptado al riesgo <strong>de</strong>l Grupo PETHEMA<br />
Durada: 3 anys - (2010-2013)<br />
Pàgina 66 <strong>de</strong> 148